CCM
ALXN

Channing Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Channing Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-59,823
Closed -$6.47M – 128
2019
Q4 		$6.47M Sell
59,823
-19,281
-24% -$2.06M 0.3% 95
2019
Q3 		$7.75M Buy
79,104
+7,816
+11% +$881K 0.36% 78
2019
Q2 		$9.34M Buy
71,288
+2,666
+4% +$344K 0.43% 58
2019
Q1 		$9.28M Sell
68,622
-26,659
-28% -$3.31M 0.43% 53
2018
Q4 		$9.28M Sell
95,281
-1,624
-2% -$192K 0.46% 50
2018
Q3 		$13.5M Sell
96,905
-3,285
-3% -$412K 0.49% 41
2018
Q2 		$12.4M Sell
100,190
-17,883
-15% -$2.09M 0.44% 48
2018
Q1 		$13.2M Sell
118,073
-7,205
-6% -$861K 0.46% 56
2017
Q4 		$15M Buy
+125,278
New +$15.3M 0.51% 53
2017
Q2 		– Sell
-96,533
Closed -$11.7M – 109
2017
Q1 		$11.7M Buy
96,533
+1,332
+1% +$172K 0.43% 62
2016
Q4 		$11.6M Buy
+95,201
New +$11.6M 0.41% 63

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Channing Capital Management's ALXN Position: Q1 2020 in Review

Channing Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2020, closing a stake of 59,823 shares — an estimated $6.47M sold.

Channing Capital Management first reported a position in ALXN in Q4 2016 and held it in 11 quarters. The position peaked at $15M in Q4 2017. 654 funds tracked by Wall St. Rank hold ALXN as of Q1 2020.

  • Channing Capital Management reported no remaining Alexion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Channing Capital Management sold 59,823 Alexion Pharmaceuticals shares in Q1 2020, an estimated $6.47M.
  • Channing Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 11 quarters.
  • Channing Capital Management's Alexion Pharmaceuticals position peaked at $15M in Q4 2017.
  • 654 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2020.

Based on Channing Capital Management's 13F filing for Q1 2020, filed 13 May 2020.